Context Therapeutics Inc. (CNTX)

NASDAQ: CNTX · IEX Real-Time Price · USD
1.490
-0.030 (-1.97%)
Apr 12, 2024, 4:00 PM EDT - Market closed
-1.97%
Market Cap 23.79M
Revenue (ttm) n/a
Net Income (ttm) -23.96M
Shares Out 15.97M
EPS (ttm) -1.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 114,997
Open 1.480
Previous Close 1.520
Day's Range 1.415 - 1.580
52-Week Range 0.470 - 1.690
Beta 2.17
Analysts Strong Buy
Price Target 4.00 (+168.46%)
Earnings Date May 8, 2024

About CNTX

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 20, 2021
Employees 5
Stock Exchange NASDAQ
Ticker Symbol CNTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for CNTX stock is "Strong Buy." The 12-month stock price forecast is $4.0, which is an increase of 168.46% from the latest price.

Price Target
$4.0
(168.46% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Important Regulatory Milestone Supports Next Phase of CTIM-76 Development Important Regulatory Milestone Supports Next Phase of CTIM-76 Development

13 days ago - GlobeNewsWire

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations into l...

24 days ago - GlobeNewsWire

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

CTIM-76 IND filing on track for late Q1 2024 Cash and cash equivalents of $21.7 million as of September 30, 2023 Company expects its cash and cash equivalents will continue to fund operations into lat...

5 months ago - GlobeNewsWire

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announce...

7 months ago - GlobeNewsWire

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Company expects its cash and cash equivalents will continue to fund operations into late 2024 Cash and cash equivalents of $25.1 million as of June 30, 2023 CTIM-76 IND filing on track for Q1 2024 PHI...

8 months ago - GlobeNewsWire

Context Therapeutics to Participate in Two August 2023 Investor Conferences

PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company dedicated to improving the lives of patients living w...

9 months ago - GlobeNewsWire

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

CTIM-76 IND filing on track for Q1 2024 Preclinical data on CLDN6 bispecific antibody CTIM-76 presented at AACR Annual Meeting 2023 Cash and cash equivalents of $29.8 million as of March 31, 2023 PHIL...

1 year ago - GlobeNewsWire

Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference

PHILADELPHIA, PA / ACCESSWIRE / April 18, 2023 / Context Therapeutics Inc. (NASDAQ:CNTX) is a biopharmaceutical company committed to advancing medicines for solid tumors by harnessing novel and innova...

1 year ago - Accesswire

Context Therapeutics to Participate in Two April 2023 Investor Conferences

PHILADELPHIA, April 03, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today ...

1 year ago - GlobeNewsWire

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

Company prioritizing pipeline to focus on CTIM-76 development and discontinuing ONA-XR program

1 year ago - GlobeNewsWire

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Context to host webinar with AACR presenter on Monday, April 17, 2023, at 4:30 p.m. ET Context to host webinar with AACR presenter on Monday, April 17, 2023, at 4:30 p.m. ET

1 year ago - GlobeNewsWire

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

ONA-XR initial data signals positive clinical activity and confirmed tumor shrinkage

1 year ago - GlobeNewsWire

Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

First endocrine innovation in more than 20 years which  has shown improved efficacy over standard-of-care treatments in patients with advanced breast cancer

1 year ago - GlobeNewsWire

Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

Lonza to support the development and manufacturing of CTIM-76, Context's CLDN6 x CD3 bispecific antibody clinical candidate

1 year ago - GlobeNewsWire

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate

1 year ago - GlobeNewsWire

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Data presented at San Antonio Breast Cancer Symposium ® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or third-line metastatic breast cancer

1 year ago - GlobeNewsWire

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

CTIM-76 named as lead candidate to target Claudin 6 positive cancers

1 year ago - GlobeNewsWire

Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium

Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for metastatic breast cancer will be presented Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for met...

1 year ago - GlobeNewsWire

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

Company reports preliminary ONA-XR data from two ongoing Phase 2 trials

1 year ago - GlobeNewsWire

Context Therapeutics to Participate in the ThinkEquity Conference

Philadelphia, Pennsylvania--(Newsfile Corp. - October 20, 2022) - Context Therapeutics Inc. (NASDAQ: CNTX) ("Context" or the "Company"), a women's oncology company developing novel treatments for brea...

1 year ago - Newsfile Corp

Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024

Company to focus resources on advancing ONA-XR ELONA Phase 1b/2 clinical trial and on advancing CLDN6xCD3 bispecific antibody toward IND Company to focus resources on advancing ONA-XR ELONA Phase 1b/2...

1 year ago - GlobeNewsWire

Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women's oncology company developing novel treatments for breast and gynecologi...

1 year ago - GlobeNewsWire

Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results

Announced new clinical trial collaboration with Menarini Group to evaluate ONA-XR plus elacestrant in metastatic breast cancer

1 year ago - GlobeNewsWire

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 PHILADELPHIA and FLOREN...

1 year ago - PRNewsWire

Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results

Abstract on results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary accepted for oral presentation at the 2022 ASCO Annual Meeting

2 years ago - GlobeNewsWire